F S&P 500
5,248.50 +9.50 (+0.18%) F Dow Jones
39,620.00 +84.00 (+0.21%) F Nasdaq
18,244.25 +29.75 (+0.16%) E-mini Russell 2000 Index Futur
2,089.30 +5.20 (+0.25%) Petróleo
79.83 +0.57 (+0.72%) Oro
2,373.30 +33.00 (+1.41%)
Sagimet Biosciences Inc. (SGMT)
Fuera de horario:
Sagimet Biosciences Inc.
155 Bovet Road
Suite 303
San Mateo, CA 94402
United States
650-561-8600
https://www.sagimet.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 8
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. George W. Kemble Ph.D. | Executive Chairman of the Board | 484k | N/D | 1962 |
| Mr. David A. Happel | CEO, President & Director | 836.18k | N/D | 1962 |
| Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. | Chief Medical Officer | 649.33k | N/D | 1963 |
| Mr. Urs Greber Ph.D. | Co-Founder | N/D | N/D | N/D |
| Dr. Lucas Pelkmans Ph.D. | Co-Founder | N/D | N/D | N/D |
| Ms. Elizabeth Rozek Esq., J.D. | General Counsel & Chief Compliance Officer | N/D | N/D | 1972 |
| Dr. Marie O'Farrell Ph.D. | Senior Vice President of Research & Development | N/D | N/D | N/D |
Descripción
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Sagimet Biosciences Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
